Advertisement

Topics

Search Results for "Colchicine And Rivaroxaban"

16:14 EDT 28th July 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Cardiac Events in Patients with Gout Treated with Colchicine

Cardiovascular risks were lower with colchicine use, in an observational study from a single medical center.

BMJ Investigation Casts Doubt on Validity of Rivaroxaban Trial

New questions have been raised about the validity and reliability of data in the ROCKET-AF trial, which serves as the backbone for the approval of rivaroxaban (Xarelto), according to an investigation ...

Rivaroxaban in the Real World

A large Phase IV registry study shows that rivaroxaban is associated with a very low incidence of major bleeding, death, or stroke. Also, adherence to therapy was much higher than observed in other st...

Rivaroxaban: It's Not Time to Cut the Rope, Yet

The warfarin arm of the ROCKET AF trial used a faulty INR device, leading to calls for independent verification of the study. Dr Mandrola agrees but is reassured by the real-world data on rivaroxa...

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

Rivaroxaban Saves Hospitals Money for VTE Admissions: Study

U.S. hospitals save money when they use the novel oral anticoagulant rivaroxaban instead of warfarin to treat patients with venous thromboembolism (VTE), a new analysis finds. Reuters Health Informa...

BRIEF-Bayer says patent term for Rivaroxaban extended in United States

* Says patent term for Rivaroxaban extended in us Further company coverage:

Management of Oral Anticoagulation in Atrial Fibrillation Patients with Worsening Renal Function

Approximately 25% of atrial fibrillation patients in a large trial comparing rivaroxaban to warfarin developed worsening renal failure during follow-up. Those treated with rivaroxaban had less embolic...

Matching PubMed Articles

Colchicine for prevention of cardiovascular events.

Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...

In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.

Four-factor prothrombin complex concentrate (PCC) 50 iu/kg is able to swiftly restore haemostatic parameters in healthy subjects on rivaroxaban. We hypothesized that lower dosages of PCC may be suffic...

A high performance thin layer chromatographic method for the estimation of colchicine in different formulations.

Colchicine is a main alkaloid present in bitter and sweet variety of colchicum (Colchicum luteum Baker), which have been reported to possess anti-rheumatic, anti-gout, and anticancer potential. Colchi...

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...

Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.

Tubulin isotypes are found to play an important role in regulating microtubule dynamics. The isotype composition is also thought to contribute in the development of drug resistance as tubulin isotypes...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement